Cargando…

A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody

Although immunotherapy has achieved great clinical success in clinical outcomes, especially the anti-PD-1 or anti-PD-L1 antibodies, not all patients respond to anti-PD-1 immunotherapy. It is urgently required for a clinical diagnosis to develop non-invasive imaging meditated strategy for assessing t...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Songbing, Yu, Yang, Guan, Hui, Yang, Yanling, Sun, Fenghao, Sun, Yan, Zhu, Jiaxing, Xing, Ligang, Yu, Jinming, Sun, Xiaorong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148448/
https://www.ncbi.nlm.nih.gov/pubmed/33910164
http://dx.doi.org/10.18632/aging.202981
_version_ 1783697840329981952
author Qin, Songbing
Yu, Yang
Guan, Hui
Yang, Yanling
Sun, Fenghao
Sun, Yan
Zhu, Jiaxing
Xing, Ligang
Yu, Jinming
Sun, Xiaorong
author_facet Qin, Songbing
Yu, Yang
Guan, Hui
Yang, Yanling
Sun, Fenghao
Sun, Yan
Zhu, Jiaxing
Xing, Ligang
Yu, Jinming
Sun, Xiaorong
author_sort Qin, Songbing
collection PubMed
description Although immunotherapy has achieved great clinical success in clinical outcomes, especially the anti-PD-1 or anti-PD-L1 antibodies, not all patients respond to anti-PD-1 immunotherapy. It is urgently required for a clinical diagnosis to develop non-invasive imaging meditated strategy for assessing the expression level of PD-L1 in tumors. In this work, a (68)Ga-labeled single-domain antibody tracer, (68)Ga-NOTA-Nb109, was designed for specific and noninvasive imaging of PD-L1 expression in an MC38 tumor-bearing mouse model. Comprehensive studies including Positron Emission Tomography (PET), biodistribution, blocking studies, immunohistochemistry, and immunotherapy, have been performed in differences PD-L1 expression tumor-bearing models. These results revealed that (68)Ga-NOTA-Nb109 specifically accumulated in the MC38-hPD-L1 tumor. The content of this nanobody in MC38 hPD-L1 tumor and MC38 Mixed tumor was 8.2 ± 1.3, 7.3 ± 1.2, 3.7 ± 1.5, 2.3 ± 1.2%ID/g and 7.5 ± 1.4, 3.6 ± 1.7, 1.7 ± 0.6, 1.2 ± 0.5%ID/g at 0.5, 1, 1.5, 2 hours post-injection, respectively. (68)Ga-NOTA-Nb109 has the potential to further noninvasive PET imaging and therapy effectiveness assessments based on the PD-L1 status in tumors. To explore the possible synergistic effects of immunotherapy combined with chemotherapy, MC38 xenografts with different sensitivity to PD-L1 blockade were established. In addition, we found that PD-1 blockade also had efficacy on the PD-L1 knockout tumors. RT-PCR and immunofluorescence analysis were used to detect the expression of PD-L1. It was observed that both mouse and human PD-L1 expressed among three types of MC38 tumors. These results suggest that PD-L1 on tumor cells affect the efficacy, but it on host myeloid cells might be essential for checkpoint blockade. Moreover, anti–PD-1 treatment activates tumor-reactive CD103(+) CD39(+) CD8+T cells (TILs) in tumor microenvironment.
format Online
Article
Text
id pubmed-8148448
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-81484482021-05-26 A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody Qin, Songbing Yu, Yang Guan, Hui Yang, Yanling Sun, Fenghao Sun, Yan Zhu, Jiaxing Xing, Ligang Yu, Jinming Sun, Xiaorong Aging (Albany NY) Research Paper Although immunotherapy has achieved great clinical success in clinical outcomes, especially the anti-PD-1 or anti-PD-L1 antibodies, not all patients respond to anti-PD-1 immunotherapy. It is urgently required for a clinical diagnosis to develop non-invasive imaging meditated strategy for assessing the expression level of PD-L1 in tumors. In this work, a (68)Ga-labeled single-domain antibody tracer, (68)Ga-NOTA-Nb109, was designed for specific and noninvasive imaging of PD-L1 expression in an MC38 tumor-bearing mouse model. Comprehensive studies including Positron Emission Tomography (PET), biodistribution, blocking studies, immunohistochemistry, and immunotherapy, have been performed in differences PD-L1 expression tumor-bearing models. These results revealed that (68)Ga-NOTA-Nb109 specifically accumulated in the MC38-hPD-L1 tumor. The content of this nanobody in MC38 hPD-L1 tumor and MC38 Mixed tumor was 8.2 ± 1.3, 7.3 ± 1.2, 3.7 ± 1.5, 2.3 ± 1.2%ID/g and 7.5 ± 1.4, 3.6 ± 1.7, 1.7 ± 0.6, 1.2 ± 0.5%ID/g at 0.5, 1, 1.5, 2 hours post-injection, respectively. (68)Ga-NOTA-Nb109 has the potential to further noninvasive PET imaging and therapy effectiveness assessments based on the PD-L1 status in tumors. To explore the possible synergistic effects of immunotherapy combined with chemotherapy, MC38 xenografts with different sensitivity to PD-L1 blockade were established. In addition, we found that PD-1 blockade also had efficacy on the PD-L1 knockout tumors. RT-PCR and immunofluorescence analysis were used to detect the expression of PD-L1. It was observed that both mouse and human PD-L1 expressed among three types of MC38 tumors. These results suggest that PD-L1 on tumor cells affect the efficacy, but it on host myeloid cells might be essential for checkpoint blockade. Moreover, anti–PD-1 treatment activates tumor-reactive CD103(+) CD39(+) CD8+T cells (TILs) in tumor microenvironment. Impact Journals 2021-04-27 /pmc/articles/PMC8148448/ /pubmed/33910164 http://dx.doi.org/10.18632/aging.202981 Text en Copyright: © 2021 Qin et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Qin, Songbing
Yu, Yang
Guan, Hui
Yang, Yanling
Sun, Fenghao
Sun, Yan
Zhu, Jiaxing
Xing, Ligang
Yu, Jinming
Sun, Xiaorong
A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody
title A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody
title_full A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody
title_fullStr A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody
title_full_unstemmed A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody
title_short A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody
title_sort preclinical study: correlation between pd-l1 pet imaging and the prediction of therapy efficacy of mc38 tumor with (68)ga-labeled pd-l1 targeted nanobody
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148448/
https://www.ncbi.nlm.nih.gov/pubmed/33910164
http://dx.doi.org/10.18632/aging.202981
work_keys_str_mv AT qinsongbing apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT yuyang apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT guanhui apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT yangyanling apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT sunfenghao apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT sunyan apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT zhujiaxing apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT xingligang apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT yujinming apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT sunxiaorong apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT qinsongbing preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT yuyang preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT guanhui preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT yangyanling preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT sunfenghao preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT sunyan preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT zhujiaxing preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT xingligang preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT yujinming preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody
AT sunxiaorong preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody